Table 4.
Comparison of baseline characteristics in one-to-one matched pairs of users and non-users of mTOR inhibitors.
| + mTOR inhibitor n=78 |
−mTOR inhibitor n=78 |
P | |
|---|---|---|---|
| Post-transplant duration, months | 74 ± 56 | 73 ± 51 | 0.88 |
| < 50 months, n (%) | 33 (42) | 33 (42) | |
| 50–99 months, n (%) | 26 (33) | 25 (32) | |
| > 99 months, n (%) | 19 (25) | 20 (26) | |
|
| |||
| Age, years | 53.3 ± 9.6 | 53.8 ± 11.1 | 0.78 |
|
| |||
| Diabetes, n (%) | 13 (17) | 10 (13) | 0.50 |
|
| |||
| Deceased donor transplant, n (%) | 75 (96) | 76 (97) | 0.65 |
|
| |||
| History of acute rejection, n (%) | 28 (36) | 26 (33) | 0.74 |
|
| |||
| HLA A mismatches, n (%) | 0.58 | ||
| 0 | 6 (8) | 4 (5) | |
| 1 | 46 (59) | 52 (67) | |
| 2 | 26 (33) | 22 (28) | |
|
| |||
| HLA B mismatches, n (%) | 1.0 | ||
| 0 | 8 (10) | 8 (10) | |
| 1 | 48 (62) | 48 (62) | |
| 2 | 22 (28) | 22 (28) | |
|
| |||
| HLA DR mismatches, n (%) | 0.09 | ||
| 0 | 24 (31) | 18 (23) | |
| 1 | 44 (56) | 56 (72) | |
| 2 | 10 (13) | 4 (5) | |
|
| |||
| eGFR, ml/min/1.73m2 | 47 ± 21 | 45 ± 19 | 0.57 |
|
| |||
| Current malignancy, n (%) | 13 (17) | 15 (19) | 0.68 |
|
| |||
| Charlson comorbidity index | 3 (2, 5) | 3 (2, 5) | 0.82 |